Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy

Dorward J. et al, (2024), Journal of Acquired Immune Deficiency Syndromes, 95, E8 - E11

Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Hayward G. et al, (2024), Journal of Infection, 88

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir-based antiretroviral therapy

Dorward J. et al, (2024), AIDS, 38, 697 - 702

Early HIV viral suppression associated with subsequent 12‐month treatment success among people living with HIV in South Africa

Violette LR. et al, (2024), HIV Medicine

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Standing JF. et al, (2024), Nature communications, 15

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial.

Png ME. et al, (2024), Br J Gen Pract

Changes in the medical admissions and mortality amongst children in four South African hospitals following the COVID-19 pandemic : A five-year review

Loganathan NK. et al, (2023)

Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa.

Asare K. et al, (2023), Open Forum Infect Dis, 10

Clinical outcomes after extended 12-month antiretroviral therapy prescriptions in a community-based differentiated HIV service delivery programme in South Africa: a retrospective cohort study

Lewis L. et al, (2023), Journal of the International AIDS Society, 26

Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy

Dorward J. et al, (2023), Journal of the International AIDS Society, 26

Point-of-Care Viral Load Testing to Manage HIV Viremia during the Rollout of Dolutegravir-Based ART in South Africa: A Randomized Feasibility Study (POwER)

Dorward J. et al, (2023), Journal of Acquired Immune Deficiency Syndromes, 93, 403 - 412

Platform adaptive trial of novel antivirals for early treatment of COVID-19 in the community (PANORAMIC): Protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease

Gbinigie O. et al, (2023), BMJ Open, 13

Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral therapy in South Africa: a retrospective cohort study.

Asare K. et al, (2023), medRxiv

Long-term usage patterns and clinical outcomes in a community-based differentiated antiretroviral therapy delivery programme in South Africa

Lewis L. et al, (2023), Journal of the International AIDS Society, 26

Delivery of Community-based Antiretroviral Therapy to Maintain Viral Suppression and Retention in Care in South Africa

Wang M. et al, (2023), Journal of Acquired Immune Deficiency Syndromes, 93, 126 - 133

Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study

Dorward J. et al, (2023), The Lancet HIV, 10, e284 - e294

Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial

Asare K. et al, (2023), Clinical Infectious Diseases, 76, 881 - 889

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Butler CC. et al, (2023), The Lancet, 401, 281 - 293

Clinical outcomes after extended 12-month antiretroviral therapy prescriptions in a community-based differentiated HIV service delivery programme in South Africa: a retrospective cohort study

Lewis L. et al, (2023)

Clinical outcomes after viraemia among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy in South Africa

Asare K. et al, (2023)

Load More

1
2
3
4
5